GRANULES

June 20 (Reuters) - Granules India Ltd GRAN.NS:

• BONTHAPALLY FACILITY COMPLETES US FDA INSPECTION

• FACILITY COMPLETED FDA INSPECTION WITH ONE 483 OBSERVATION

Source text: ID:nNSEbcFQWR

Further company coverage: GRAN.NS

(([email protected];;))

** Indian pharma stocks .NIPHARM gain 1.4%

** Donald Trump signs executive order directing drugmakers to lower prices of their medicines to align with what other countries pay

** But, the order was not as bad as feared, investors, analysts and drug pricing experts said

** Pharma stocks declined in early trade on Monday after Trump's announcement

** HDFC Securities says generic drugmakers unlikely to have any impact

** Adds Sun Pharma SUN.NS to see some impact of price ceiling on specialty products like psoriasis drug Ilumya and anti-baldness drug Leqselvi

** Glenmark Pharma GLEN.NS, Divi's Laboratories DIVI.NS climb 3% each; SUN rises 0.6%

** Lupin LUPN.NS, Granules India GRAN.NS and Biocon BION.NS gain 2.6%, 3.8% and 1.7% respectively

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

April 10 (Reuters) - Granules India Ltd GRAN.NS:

• CLOSING OF ACQUISITION OF SENN CHEMICALS

Further company coverage: GRAN.NS

(([email protected];))

March 25 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - BOARD APPROVES INTERNAL RESTRUCTURING PLAN FOR US SUBSIDIARIES

• GRANULES INDIA LTD - NO CHANGE IN ULTIMATE OWNERSHIP OR BUSINESS NATURE IN US

Source text: ID:nBSE3nGBP8

Further company coverage: GRAN.NS

(([email protected];))

March 18 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT GRANULES EUROPE HAS BEEN VOLUNTARILY DISSOLVED

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of pharma co Granules India GRAN.NS fall 2.4% to 460 rupees

** Stock among top losers on Nifty Pharma index .NIPHARM

** The US FDA issued a warning letter to co post inspection

** Reports says bird droppings and feathers were found on air purification units, ducts, tank etc

** Flagged issues including lack of written procedures for equipment cleaning, residues and microbial contamination in ducts, risking cross-contamination

** More than 2.2 mln shares change hands, 1.6x its 30-day avg

** Stock down ~21% YTD vs a ~15% drop in NIPHARM

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

** Shares of Granules India GRAN.NS slide as much as 7% to 471.5 rupees, their lowest in eight months

** Stock last down 6.6%; biggest pct loser on Nifty pharma index .NIPHARM, which is down 1.3%

** Pharma co's Gagillapur facility gets US FDA warning letter based on inspection conducted in August 2024

** The warning letter may temporarily impact the FDA review of pending product submissions from this site until the issue is resolved - GRAN

** The U.S. FDA classified the facility as "official action indicated", sending its shares down over 10%, on December 3

** GRAN stock has fallen ~11% since December 3

** Four brokerages' avg rating on stock is "strong buy", median PT is 657.5 rupees - data compiled by LSEG

** Year-to-date, GRAN down 14%; Nifty pharma index also 14% lower

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

** Shares of Granules India GRAN.NS climb 2.2% to 520 rupees

** Pharma co says it signed agreement to acquire Switzerland-based Senn Chemicals AG

** Co adds, acquisition is expected to close in the

first half of 2025

** Financial details of the deal was not disclosed

** Stock set to log gains after falling for two straight sessions

** Stock down ~14% YTD vs ~13% fall in broader Nifty Pharma index .NIPHARM

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Feb 21 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - TO ACQUIRE 100% EQUITY STAKE IN SENN CHEMICALS AG

• GRANULES: DEAL FOR 1.93 BILLION RUPEES

Source text: ID:nNSE1PXl9y

Further company coverage: GRAN.NS

(([email protected];;))

Jan 30 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - FDA APPROVAL FOR LISDEXAMFETAMINE DIMESYLATE CAPSULES

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];))

Jan 29 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT V RECEIVES EU GMP CERTIFICATE

• EU AUTHORITY CONDUCTED AUDIT OF GRANULES INDIA UNIT V IN NOVEMBER 2024

Source text: ID:nBSE5nkvmM

Further company coverage: GRAN.NS

(([email protected];;))

Jan 24 (Reuters) - Granules India Ltd GRAN.NS:

• Q3 CONSOL PROFIT 1.18 BILLION RUPEES

• Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 11.38 BILLION RUPEES

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of Granules India GRAN.NS turn positive, up 0.7% at 588.40 rupees

** Pharma co's unit gets US FDA's approval for Lisdexamfetamine Dimesylate chewable tablets, a generic for Vyvanse chewable tablets

** Lisdexamfetamine dimesylate tablets are used to treat attention deficit hyperactivity disorder and binge eating disorder

** Stock was down ~0.5% before disclosure of US FDA approval for unit's drug

** GRAN up ~45% YTD vs gains of 27% in 2023

(Reporting by Vijay Malkar)

(([email protected];))

Dec 4 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - UPDATE ON US FDA INSPECTION AT GAGILLAPUR FACILITY

• GRANULES INDIA LTD - OAI CLASSIFICATION DOES NOT IMPACT ONGOING MANUFACTURING OR DISTRIBUTION

• GRANULES INDIA LTD - OAI STATUS MAY IMPACT REVIEW OF PENDING SUBMISSIONS FOR NEW PRODUCTS

Source text: ID:nnAPN2FLDZF

Further company coverage: GRAN.NS

(([email protected];))

** Shares of pharmaceuticals maker Granules India GRAN.NS close down 10.3%

** This is only the second session this year that the stock has declined by 10% or more

** Stock top loser on the Nifty Pharma index .NIPHARM, which slips about 0.1%

** US FDA classifies inspection co's Gagillapur facility as 'official action indicated' (OAI); the classification means regulatory or administrative actions are recommended

** Co says it has responded to all observations issued by the US FDA and voluntarily undertaken evaluation of facility, in consultation with external subject matter experts

** Trading vols at 18.4 mln, highest since mid-September

** GRAN stock has risen around 32% YTD, NIPHARM also up about 33%

(Reporting by Vijay Malkar)

(([email protected];))

** Shares of Granules India GRAN.NS climb as much as 3.2% to 590.5 rupees but trim gains to trade largely flat amid drop in Nifty 50 .NSEI, which is down 0.4% .BO

** Pharma co said a U.S. FDA inspection concluded at its unit's facility in Andhra Pradesh state with zero observations

** Facility secured an establishment inspection report with "No Action Indicated" status

** Stock up 44% YTD, its biggest annual gain since 2020

** Peers Aurobindo Pharma ARBN.NS and Alembic Pharma ALEM.NS up ~23% and 45% so far this year

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Nov 6 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA Q2 CONSOL PROFIT 972.3 MILLION RUPEES

• GRANULES INDIA Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 9.67 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];))

** Shares of Granules India GRAN.NS fall as much as 16.9% to 562.10 rupees, mark sharpest intraday pct loss since March 23, 2020

** Pharmaceutical manufacturing co says several investors have sought clarification from co on U.S. FDA's observations on its Gagillapur facility

** Adds, it will work with FDA to address issues raised in the observations

** On Saturday, FDA inspection at this facility concluded with six observations

** Stock is witnessing its most active trading session since 2005 listing, with more than 35 mln shares change hands, 12.8x of 30-day avg

** Stock last down 16.6%, cutting YTD gains to 39.2%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Aug 20 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIVES ANDA APPROVAL FOR GLYCOPYRROLATE ORAL SOLUTION

Source text for Eikon: ID:nBSE1TgfBl

Further company coverage: GRAN.NS

(([email protected];))

** Shares of pharma company Granules India GRAN.NS rise as much as 3.8% to record high of 586.5 rupees

** GRAN marks sharpest intraday gain since June 18, set for seventh straight session of rise

** The company reported a near three-fold rise in June-quarter profit to 1.35 billion rupees ($16.1 million)

** "Continued growth in formulation segment, strong North America business, and product diversification offset Paracetamol API/PFI decline", Chairman Krishna Prasad Chigurupati said

** Stock last up 2.3%, taking YTD gains to 42.5%

($1 = 83.7275 Indian rupees)

(Reporting by Anisha Ajith in Bengaluru)

(([email protected];))

** Indian pharma stocks .NIPHARM up 5.3% this week, set for best weekly rise since March 2022

** Gains led by top-weighted stock Sun Pharma's SUN.NS 9% weekly jump, index heavyweight Divi's Laboratories' DIVI.NS ~6% jump and Torrent Pharma's TORP.NS 6.3% rise

** Granules India GRAN.NS top pct gainer, rising 11.7%, while Biocon BION.NS up 10%

** Eleven stocks on 20-member Nifty Pharma index .NIPHARM rated "buy" or higher, rest rated "hold" - LSEG data

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

BENGALURU, May 15 (Reuters) - Drugmaker Granules India GRAN.NS posted a 1.6% fall in fourth-quarter revenue on Wednesday, hurt by a decline in paracetamol sales and price erosion.

The company's consolidated revenue fell year-on-year to 11.76 billion rupees (nearly $141 million) for the three months to March 31.

Granules, which focuses on making active pharmaceutical ingredients (API), holds 30% of the global market for Paracetamol. It makes the drug's API as well as the finished dosage - the ready-for-consumption product.

Still, weak sales of the drug and price erosion due to heightened competition hurt its revenue. This is despite analysts expecting Indian API makers, including Granules, to benefit from increasing demand from Europe and the U.S., the industry's biggest markets.

Shares fell as much as 2.6% after it reported its results.

Rivals Glenmark Life Sciences GLEM.NS and Laurus Labs LAUL.NS posted lower fourth-quarter profits.

Glenmark's revenue was hit by issues stemming from the Red Sea crisis while Laurus was challenged by multiple factors including a decline in selling prices of antiretroviral products.

A 9.5% drop in Granules' raw material expenses, meanwhile, helped its quarterly profit climb 8.4% to 1.30 billion rupees.

API makers use a variety of chemicals in their formulations, including hydrochloric acid and chloroform, accounting for a majority of the drug-makers' input costs.

The easing costs had helped its profit marginally climb in the third quarter as well, before which profit fell for two straight quarters.

($1 = 83.4750 Indian rupees)

(Reporting by Varun Hebbalalu in Bengaluru; Editing by Janane Venkatraman )

(([email protected];))

May 1 (Reuters) - Granules India Ltd GRAN.NS:

• GETS TAX ORDER FOR TOTAL AMOUNT AT 2.1 MILLION RUPEES

Source text for Eikon: ID:nBSE7b5pyJ

Further company coverage: GRAN.NS

(([email protected];))

April 30 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIPT OF ANDA APPROVAL FOR COLCHICINE CAPSULES

• US FDA APPROVED ANDA FILED BY UNIT GRANULES PHARMACEUTICALS, INC FOR COLCHICINE CAPSULES

Source text for Eikon: ID:nBSE4HM7xD

Further company coverage: GRAN.NS

(([email protected];))

April 12 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - US FDA AUDIT FOR GRANULES INDIA’S UNIT V FACILITY RESULTS IN ZERO 483

Source text for Eikon: ID:nBSE953D8d

Further company coverage: GRAN.NS

(([email protected];))

** Shares of pharmaceutical firm Laurus Labs LAUL.NS rise as much as 7.9% to 448 rupees, highest since Nov. 28, 2022

** Stock on track for fourth consecutive session of gains

** Reuters could not immediately ascertain a reason for the move

** Stock top gainer in Nifty pharma index .NIPHARM, which is trading flat

** Stock most active since Jan. 25; more than 6.9 mln shares change hands by 1:59 p.m. IST, 3.9x the 30-day avg

** Avg rating of 10 analysts equivalent of "hold", median PT is 333 rupees - LSEG data

** Among peers, Granules India GRAN.NS rated "strong buy" while Glenmark Life Sciences GLEM.NS is rated "buy" - LSEG

** LAUL fell 8.8% in March quarter vs 12.9% rise in Nifty pharma index

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Jan 23 (Reuters) - Granules India Ltd GRAN.NS:

• DEC-QUARTER CONSOL PROFIT 1.26 BILLION RUPEES VERSUS 1.24 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.56 BILLION RUPEES VERSUS 11.46 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];))

Dec 13 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIVED ANDA APPROVAL FOR PANTOPRAZOLE SODIUM DELAYED- RELEASE TABLETS

Source text for Eikon: ID:nBSE43McLm

Further company coverage: GRAN.NS

(([email protected];))

** Shares of drugmaker Granules India GRAN.NS rises 4.6% at 387.2 rupees, their highest level since Aug 2021

** Stock sees most active day in more than two months

** A reason for the move could not be immediately ascertained

** GRAN has closed more than 4.5% up only twice this year

** In the last three months, stock up over 31% vs 4% rise in Nifty Pharma index.NIPHARM

(Reporitng by Nishit Navin)

(([email protected];))

Nov 23 (Reuters) - Granules India Ltd GRAN.NS:

• GOT ORDER FROM GST AUTHORITES DIRECTING CO TO PAY TAX, INTEREST, PENALTY WORTH 4.3 MILLION RUPEES

• NO MATERIAL IMPACT ON COMPANY DUE TO TAX LIABILITY AND PENALTY

Source text for Eikon: ID:nBSE2z98Qz

Further company coverage: GRAN.NS

(([email protected];))